AR081627A1 - Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10 - Google Patents

Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10

Info

Publication number
AR081627A1
AR081627A1 ARP110101668A ARP110101668A AR081627A1 AR 081627 A1 AR081627 A1 AR 081627A1 AR P110101668 A ARP110101668 A AR P110101668A AR P110101668 A ARP110101668 A AR P110101668A AR 081627 A1 AR081627 A1 AR 081627A1
Authority
AR
Argentina
Prior art keywords
alq
ring
nrara
halo
independently
Prior art date
Application number
ARP110101668A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer R Allen
Essa Hu
Robert M Rzasa
Wenge Zhong
Qingyian Liu
Michael J Frohn
Jian J Chen
Shannon Rumfelt
Alexander J Pickrell
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR081627(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR081627A1 publication Critical patent/AR081627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP110101668A 2010-05-13 2011-05-13 Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10 AR081627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33452510P 2010-05-13 2010-05-13

Publications (1)

Publication Number Publication Date
AR081627A1 true AR081627A1 (es) 2012-10-10

Family

ID=44278966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101668A AR081627A1 (es) 2010-05-13 2011-05-13 Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10

Country Status (26)

Country Link
US (3) US8957073B2 (enExample)
EP (1) EP2569300A1 (enExample)
JP (1) JP5702855B2 (enExample)
KR (1) KR101564806B1 (enExample)
CN (1) CN103221404B (enExample)
AR (1) AR081627A1 (enExample)
AU (1) AU2011253057B2 (enExample)
BR (1) BR112012029026A2 (enExample)
CA (1) CA2798490A1 (enExample)
CL (1) CL2012003178A1 (enExample)
CO (1) CO6630189A2 (enExample)
CR (1) CR20120635A (enExample)
EA (1) EA201291236A1 (enExample)
IL (1) IL222898A (enExample)
MA (1) MA34300B1 (enExample)
MX (1) MX2012013130A (enExample)
NZ (1) NZ603876A (enExample)
PE (1) PE20130576A1 (enExample)
PH (1) PH12012502212A1 (enExample)
SG (1) SG185515A1 (enExample)
TN (1) TN2012000530A1 (enExample)
TW (1) TW201206902A (enExample)
UA (1) UA109438C2 (enExample)
UY (1) UY33382A (enExample)
WO (1) WO2011143365A1 (enExample)
ZA (1) ZA201208510B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
JP2013526546A (ja) * 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
PE20130576A1 (es) * 2010-05-13 2013-05-19 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
BR112013030442B1 (pt) 2011-06-10 2021-11-09 Merck Patent Gmbh Compostos de pirimidina e piridina com atividade inibidora de btk, seus usos, composição, e kit
US8623860B2 (en) * 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
BR112014027805A2 (pt) * 2012-05-09 2017-06-27 Zoetis Llc derivados de azetidina como agentes antiparasitários
AR091436A1 (es) 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
US20150374687A1 (en) * 2013-02-07 2015-12-31 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
JP6602778B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105216B1 (en) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Pyrazine modulators of gpr6
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
CA2949511A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Anthelmintic compounds
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US9855249B2 (en) 2014-10-02 2018-01-02 Flatley Discovery Lab, Llc Isoxazole compounds and methods for the treatment of cystic fibrosis
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
BR112018002553A8 (pt) 2015-08-12 2023-01-24 Incyte Corp Sais de um inibidor de lsd1
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
WO2017205425A1 (en) * 2016-05-24 2017-11-30 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
PL3555064T3 (pl) * 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
CN106957300A (zh) * 2017-04-12 2017-07-18 苏州汉德创宏生化科技有限公司 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法
EP3700935A4 (en) 2017-10-25 2021-08-04 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
ES2924933T3 (es) 2017-10-27 2022-10-11 Boehringer Ingelheim Int Derivados de piridina y usos terapéuticos de los mismos como inhibidores de TRPC6
CA3091555A1 (en) * 2017-12-26 2019-07-04 Mediconns (Shanghai) Biopharmaceutical Co., Ltd Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
CA3045644C (en) 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
AU2019285570B2 (en) * 2018-06-15 2022-03-24 Pfizer Inc. GLP-1 receptor agonists and uses thereof
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
JP7485660B2 (ja) 2018-10-02 2024-05-16 シンジェンタ パーティシペーションズ アーゲー 殺有害生物性活性ベンゼン－及びアジン－アミド化合物
WO2020086456A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
CN113165139B (zh) 2018-11-26 2023-06-09 京瓷株式会社 气体喷嘴和气体喷嘴的制造方法以及等离子体处理装置
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI853009B (zh) 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物
BR112021019987A2 (pt) 2019-04-05 2021-12-07 Syngenta Crop Protection Ag Compostos de diazina-amida pesticidamente ativos
WO2020208036A1 (en) 2019-04-11 2020-10-15 Syngenta Crop Protection Ag Pesticidally active diazine-amide compounds
CR20210562A (es) 2019-04-12 2022-02-18 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
EP4578460A3 (en) * 2019-05-20 2025-08-27 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN114269732A (zh) 2019-08-23 2022-04-01 先正达农作物保护股份公司 杀有害生物活性的吡嗪-酰胺化合物
CN114728007B (zh) * 2019-09-12 2025-04-29 达萨玛治疗公司 Sarm1的抑制剂
US20230002348A1 (en) * 2019-11-15 2023-01-05 Ildong Pharmaceutical Co., Ltd. GLP-1 Receptor Agonist and Use Thereof
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
PL4097097T3 (pl) 2020-01-29 2025-05-12 Gilead Sciences, Inc. Związki modulujące glp-1r
AU2021237185B2 (en) * 2020-03-18 2023-11-30 Lg Chem, Ltd. GLP-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
EP4119555A4 (en) * 2020-03-18 2023-08-23 Lg Chem, Ltd. GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND PROCESS FOR MANUFACTURE THEREOF
CA3188340A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
KR20230088761A (ko) 2020-10-13 2023-06-20 베링거 인겔하임 인터내셔날 게엠베하 재가공하는 방법
CN116507282A (zh) * 2020-11-19 2023-07-28 睿升公司 放射性药物酮和阿尔茨海默病、认知障碍与其他脑代谢改变病症中的双示踪剂成像
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022147246A1 (en) 2020-12-30 2022-07-07 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4337682A2 (en) 2021-05-13 2024-03-20 Carmot Therapeutics Inc. Modulators of g-protein coupled receptors
BR112023025644A2 (pt) 2021-06-09 2024-02-27 Syngenta Crop Protection Ag Compostos de diazina-amida pesticidamente ativos
WO2022266162A1 (en) * 2021-06-16 2022-12-22 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
WO2022266236A1 (en) 2021-06-18 2022-12-22 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
CN118251391A (zh) 2021-09-27 2024-06-25 拓臻制药公司 作为glp-1r激动剂的苯并咪唑羧酸
JP2024541920A (ja) 2021-10-25 2024-11-13 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
TW202328139A (zh) 2021-12-16 2023-07-16 美商艾利格斯醫療公司 用於靶向ｐｄ－ｌ１之方法及組成物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
TWI866545B (zh) * 2022-10-20 2024-12-11 南韓商東亞Ｓｔ股份有限公司 氮雜環丁烷基苯并唑化合物及其等作為mer及axl抑制劑的用途
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025147609A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
DK1511710T3 (en) * 2002-05-31 2014-02-24 Proteotech Inc RELATIONSHIPS, PREPARATIONS AND METHODS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHES, SUCH AS ALZHEIMER'S DISEASE, TYPE 2-DIABETES AND PARKINSON'S DISEASE
AU2003301436A1 (en) 2002-10-17 2004-05-04 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
CA2534432A1 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
GB0325287D0 (en) 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
KR100907354B1 (ko) 2004-05-18 2009-07-10 쉐링 코포레이션 Ｐｄｅ4 억제제로서 유용한 치환된 2-퀴놀릴-옥사졸
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
WO2007076104A1 (en) * 2005-12-23 2007-07-05 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2007085954A2 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Aminophthalazine derivative compounds
JP2011507824A (ja) * 2007-12-21 2011-03-10 アストラゼネカ アクチボラグ アンドロゲン受容体関連状態の治療に使用の二環系誘導体
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JO2907B1 (en) * 2009-05-12 2015-09-15 اديكس فرما اس ايه Pyridine derivatives 1, 2, 4 trisolo [4, 3-A] and their uses as positive LLs for 2MGLUR receptors
NZ598294A (en) 2009-09-03 2013-07-26 Bioenergenix Heterocyclic compounds for the inhibition of pask
RU2012114846A (ru) * 2009-09-16 2013-10-27 Астеллас Фарма Инк. Соединение глицина
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
US8952037B2 (en) 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
PE20130576A1 (es) * 2010-05-13 2013-05-19 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
JP2013526546A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
AR091436A1 (es) * 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Also Published As

Publication number Publication date
PH12012502212A1 (en) 2013-02-04
PE20130576A1 (es) 2013-05-19
CL2012003178A1 (es) 2013-07-05
US20140213572A1 (en) 2014-07-31
CO6630189A2 (es) 2013-03-01
KR101564806B1 (ko) 2015-10-30
AU2011253057A1 (en) 2012-11-29
ZA201208510B (en) 2017-11-29
NZ603876A (en) 2015-02-27
MA34300B1 (fr) 2013-06-01
BR112012029026A2 (pt) 2016-08-02
US8957073B2 (en) 2015-02-17
AU2011253057B2 (en) 2014-11-20
WO2011143365A1 (en) 2011-11-17
JP2013526536A (ja) 2013-06-24
US20160102075A1 (en) 2016-04-14
IL222898A0 (en) 2012-12-31
EP2569300A1 (en) 2013-03-20
CN103221404A (zh) 2013-07-24
IL222898A (en) 2015-11-30
US20110306587A1 (en) 2011-12-15
UY33382A (es) 2011-10-31
SG185515A1 (en) 2012-12-28
KR20130065666A (ko) 2013-06-19
US9718803B2 (en) 2017-08-01
UA109438C2 (uk) 2015-08-25
MX2012013130A (es) 2013-04-11
CR20120635A (es) 2013-01-30
JP5702855B2 (ja) 2015-04-15
TW201206902A (en) 2012-02-16
CN103221404B (zh) 2015-12-16
EA201291236A1 (ru) 2013-11-29
TN2012000530A1 (en) 2014-04-01
CA2798490A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
AR081627A1 (es) Compuestos heterociclicos de nitrogeno insaturados utiles como inhibidores de pde10
AR067762A1 (es) Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
AR059380A1 (es) Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina, composiciones farmaceuticas
AR099994A1 (es) Compuesto de ciclopropanamina y sus usos
AR095823A1 (es) Compuesto de ciclopropanamina y uso del mismo
MX2015011618A (es) Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso.
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
CO6811860A2 (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CO7160015A2 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
AR068051A1 (es) Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer.
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AR090203A1 (es) Compuestos heterobiciclicos como inhibidores de pde10
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
AR072819A1 (es) Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR074775A1 (es) Compuestos aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
CO7141456A2 (es) Derivados de aril-sultamo como moduladores de rorc
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
AR075368A1 (es) Inhibidores de glicosilceramida sintasa
AR072820A1 (es) Derivados de imidazo[1,2-a]pirimidina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras
AR086036A1 (es) DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5)
CO6341626A2 (es) Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina

Legal Events

Date Code Title Description
FB Suspension of granting procedure